Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01988675 · ClinicalTrials.gov registry record
MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 91
- Enrollment target
NCT01988675: Completed study, sponsored by University of Michigan Rogel Cancer Center.
NCT01988675 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 91 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01988675 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
Study Summary
This is a study to determine if Magnetic Resonance Imaging (MRI) techniques can detect early changes in white matter (in the brain) and the blood-brain barrier resulting from radiation therapy.
Primary Outcome
Linear mixed models will be used to relate Magnetic Resonance Imagining (MRI) changes and radiation dose.
Interventions
- BEHAVIORAL Quality of Life Questionnaire
- DEVICE Magnetic Resonance Imaging (MRI) Assessments
- RADIATION Whole Brain Irradiation
- RADIATION Partial Brain Irradiation
- BEHAVIORAL Neuropsychological Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2004-08-26 |
| Est. Completion | 2014-06-03 |
What the finished NCT01988675 record still lists
NCT01988675 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Quality of Life Questionnaire is the first listed.
NCT01988675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01988675 about?
NCT01988675 is a clinical study titled "MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier". This is a study to determine if Magnetic Resonance Imaging (MRI) techniques can detect early changes in white matter (in the brain) and the blood-brain barrier resulting from radiation therapy.
What is the current status of trial NCT01988675?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2004-08-26. Estimated completion is 2014-06-03.
What interventions are being tested in trial NCT01988675?
The interventions under investigation include: Quality of Life Questionnaire (BEHAVIORAL), Magnetic Resonance Imaging (MRI) Assessments (DEVICE), Whole Brain Irradiation (RADIATION), Partial Brain Irradiation (RADIATION), Neuropsychological Testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT01988675?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI